What is MD Longevity?
MD Longevity operates as a premier clinical entity in New York, focusing on the intersection of regenerative medicine and personalized health optimization. Under the leadership of Dr. Ann Peters, the organization provides sophisticated bioidentical hormone replacement therapy and comprehensive weight management programs. The clinic distinguishes itself through a data-driven approach to age management, catering to a demographic increasingly focused on vitality and long-term wellness. By integrating clinical rigor with patient-centric care, MD Longevity has established a defensible market position in the high-growth anti-aging industry.
How much funding has MD Longevity raised?
MD Longevity has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
Key Investors in MD Longevity
PPP
Public-Private Partnership
What's next for MD Longevity?
With the infusion of this recent capital, MD Longevity is well-positioned to scale its clinical infrastructure and broaden its therapeutic portfolio. The strategic roadmap likely involves the deployment of advanced diagnostic tools and the expansion of its regenerative medicine capabilities to meet rising demand for personalized health interventions. As the company transitions through this significant Series B/C stage, the focus will remain on maintaining high-touch patient outcomes while exploring potential geographic or service-line diversification. This financial backing provides the necessary runway to refine its proprietary treatment protocols and strengthen its competitive advantage in the premium wellness market.
See full MD Longevity company page
